Silver Book Fact

High-intensity ultrasonic cyclocoagulation reduces intraocular pressure in refractory glaucoma patients.

Aptel F, Charrell T, Lafon C, Ramano F, et al. Miniaturized High-Intensity Focused Ultrasound Device in Patients with Glaucoma: A clinical pilot study. Invest Opthalmol Vis Sci. 2011; 52(12): 8747-8753. http://iovs.arvojournals.org/article.aspx?articleid=2187000

Reference

Title
Miniaturized High-Intensity Focused Ultrasound Device in Patients with Glaucoma: A clinical pilot study
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Aptel F, Charrell T, Lafon C, Ramano F, et al
Volume & Issue
Volume 52, Issue 12
Pages
8747-8753
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • Increase in AMD risk for people with a high dGI
    A recent study showed that there was a 49% increase in the risk of advanced AMD for people with a dGI (dietary glycemic index) higher than the sex median (women…  
  • The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about…  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.